Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br ASK in Huntington s disease and other
2024-08-19

ASK1 in Huntington's disease and other polyglutamine diseases The polyglutamine (polyQ) diseases are a group of inherited neurodegenerative disorders caused by the expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats in the coding regions of specific genes, leading to the production
-
br Introduction The term antioxidant derives from
2024-08-19

Introduction The term antioxidant derives from the prevention of the oxygen consumption. In the late of 19th centuries, antioxidants were generally used in industrial processes such as against to metal corrosion, vulcanization of rubber. Later on, the use of antioxidants to prevent the rancidity
-
br Conclus o br Conflitos de interesses br Alzheimer Disease
2024-08-19

Conclusão Conflitos de interesses Alzheimer Disease: Common and Complex Alzheimer’s disease (AD) is a genetically complex, multifactorial disease that leads to neurodegenerative dementia. There is no cure for AD yet, and due to a high prevalence and continuously increasing incidence it pose
-
In summary we identified a novel MLPH
2024-08-19

In summary, we identified a novel MLPH-ALK fusion in AST with discordant results of ALK IHC. In order not to overlook ALK-rearranged AST with rare fusion partners on IHC screening, a sensitive IHC method is preferable. Introduction Lung cancer remains the leading cause of cancer related deaths w
-
Despite these efforts to prevent oxidative metabolic degrada
2024-08-17

Despite these efforts to prevent oxidative metabolic degradation, and showed only marginal improvements in metabolic stability and still exhibited high plasma clearances as shown in . High molecular weight as well as relative high log values could be contributing factors to the poor PK profiles of a
-
br Conclusion In this brief Letter we
2024-08-17

Conclusion In this brief Letter, we report an easy method for the preparation of the antileukemic natural product 1. Using a biomimetic strategy,1, 8 in which the aromatic residues are attached to a lysine moiety prior to the reduction of the central carboxylate group, a step-economical synthesis
-
Given the profound expression of HT A
2024-08-17

Given the profound Fmoc-Val-OH of 5-HT1A and 5-HT2A in the hippocampal CA1 region, and their potential to complex with mGluRs, the objective of this study was to examine if sleep deprivation alters the expression of 5-HT1A and 5-HT2A receptors and determine whether potential changes are reversible p
-
The most potent compounds within
2024-08-17

The most potent compounds within the current series of compounds were therefore , , , , and , with live dead stain possessing the best selectivity towards the lyase reaction in comparison to the hydroxylase reaction, indeed, this compound was found to possess an IC value of 1210nM against the 17α
-
Cy7 NHS ester (non-sulfonated) The consensus amino acid reco
2024-08-17

The consensus amino Cy7 NHS ester (non-sulfonated) recognition sequence for p38α substrates is (Ser/Thr)Pro (Cuadrado and Nebreda, 2010), typically assisted by upstream docking motifs (Remenyi et al, 2005, Sharrocks et al, 2000). P450c17 has 32 Ser and 25 Thr residues, of which only Thr 341 and Ser
-
Here we report discovery of
2024-08-17

Here we report discovery of highly selective pan-Aurora kinase inhibitors through phenotypic screening. The co-crystal structure of Pexmetinib mg bound in the ATP binding site of Aurora A is described, and provides insight into the possible structural basis for the selectivity of the interaction.
-
br Breast cancer The interactions between LOX and
2024-08-17

Breast cancer The interactions between 15-LOX and COX enzymes also affect the outcome of breast cancer. Indomethacin, a COX-1 and COX-2 inhibitor, decreased the growth of human breast cancer (BC) cells in nude mice, as well as slowed the rate of lung metastasis formation [41]. The levels of 12-HE
-
Introduction the DNA damage response important
2024-08-17

Introduction: the DNA damage response — important implications for tumour development and treatment Cells are invariably challenged by tens of thousands of lesions inflicted on their DNA everyday (Lindhal, 1993). This DNA damage can be caused exogenously by exposure to different types of radiation
-
br Concluding remarks It is clear that a
2024-08-17

Concluding remarks It is clear that a disordered l-arginine homeostasis by changes in arginase, NOS and ADMA activity and expression, is not only vital in the chronic airway diseases, 7-Ethyl-10-hydroxycamptothecin mg and COPD, but also seems to play an important role in many co-morbidities. Unk
-
The alamarBlue test revealed that recombinant apelin led
2024-08-17

The alamarBlue test revealed that recombinant apelin led to an increase in basal and IGF1- and FHS-induced ovarian cell proliferation. Apelin increased ERK1/2 and Akt protein expression, but cell proliferation returned to control levels in the presence of kinase inhibitors. This suggests that the pr
-
br Results br Discussion Evaluation of antimicrobial
2024-08-16

Results Discussion Evaluation of antimicrobial usage is standardized using the DDD as a recommended strategy for comparison with similar hospitals [13]. The use of risk adjustment is needed to overcome the challenge of benchmarking. Two patient characteristics are associated with clinical outc
15815 records 106/1055 page Previous Next First page 上5页 106107108109110 下5页 Last page